ES2572215T3 - Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico - Google Patents

Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico

Info

Publication number
ES2572215T3
ES2572215T3 ES12729030T ES12729030T ES2572215T3 ES 2572215 T3 ES2572215 T3 ES 2572215T3 ES 12729030 T ES12729030 T ES 12729030T ES 12729030 T ES12729030 T ES 12729030T ES 2572215 T3 ES2572215 T3 ES 2572215T3
Authority
ES
Spain
Prior art keywords
mat3
prolactin receptor
antibody against
therapeutic use
neutralizing antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12729030T
Other languages
English (en)
Inventor
Christoph Freiberg
Christiane Otto
Lars Linden
Axel Harrenga
Mark Trautwein
Simone Greven
Andreas Wilmen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Application granted granted Critical
Publication of ES2572215T3 publication Critical patent/ES2572215T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

El anticuerpo Mat3 o fragmentos de unión a antígeno del mismo, que antagonizan la señalización mediada por el receptor de prolactina, en el que el anticuerpo o los fragmentos de unión a antígeno comprenden a. una región variable pesada con una secuencia de aminoácidos de acuerdo con la SEQ ID NO: 1, y b. una región variable ligera con una secuencia de aminoácidos de acuerdo con la SEQ ID NO: 2.
ES12729030T 2011-06-03 2012-05-31 Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico Active ES2572215T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11168644A EP2530089A1 (en) 2011-06-03 2011-06-03 Neutralising prolactin receptor antibody Mat3 and its therapeutical use
PCT/EP2012/060078 WO2012163932A1 (en) 2011-06-03 2012-05-31 Neutralizing prolactin receptor antibody mat3 and its therapeutic use

Publications (1)

Publication Number Publication Date
ES2572215T3 true ES2572215T3 (es) 2016-05-30

Family

ID=46331236

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12729030T Active ES2572215T3 (es) 2011-06-03 2012-05-31 Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico

Country Status (37)

Country Link
US (2) US9353186B2 (es)
EP (2) EP2530089A1 (es)
JP (1) JP5859641B2 (es)
KR (1) KR101920521B1 (es)
CN (1) CN103764679B (es)
AP (1) AP2013007266A0 (es)
AR (1) AR086631A1 (es)
AU (1) AU2012264765B2 (es)
BR (1) BR112013030995B1 (es)
CA (1) CA2837736C (es)
CL (1) CL2013003459A1 (es)
CO (1) CO6852025A2 (es)
CR (1) CR20130632A (es)
CU (1) CU20130163A7 (es)
CY (1) CY1117660T1 (es)
DK (1) DK2714740T3 (es)
DO (1) DOP2013000285A (es)
EA (1) EA029316B1 (es)
EC (1) ECSP13013063A (es)
ES (1) ES2572215T3 (es)
HK (1) HK1195081A1 (es)
HR (1) HRP20160506T1 (es)
HU (1) HUE028775T2 (es)
IL (1) IL229504B (es)
MA (1) MA35237B1 (es)
ME (1) ME02659B (es)
MX (1) MX343683B (es)
PE (1) PE20141158A1 (es)
PL (1) PL2714740T3 (es)
RS (1) RS54727B1 (es)
SG (1) SG195060A1 (es)
SI (1) SI2714740T1 (es)
TN (1) TN2013000501A1 (es)
TW (1) TWI548649B (es)
UY (1) UY34116A (es)
WO (1) WO2012163932A1 (es)
ZA (1) ZA201309683B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014022692A8 (pt) 2012-03-14 2021-07-20 Regeneron Pharma molécula de ligação de antígeno multiespecífica
RS57259B1 (sr) * 2012-12-24 2018-08-31 Abbvie Inc Prolaktin receptor vezujući proteini i njihova upotreba
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
NZ737726A (en) 2015-07-06 2023-03-31 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
IL266917B2 (en) 2016-11-29 2023-10-01 Regeneron Pharma Conjugates of a drug and an antibody to the human prolactin receptor (PRLR) and their use in the combined treatment of PRLR-positive breast cancer
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
JP2020527552A (ja) 2017-07-10 2020-09-10 バイエル・ファルマ・アクティエンゲゼルシャフト 男性型脱毛症および女性型脱毛症用のプロラクチン受容体抗体
UY37757A (es) * 2017-08-10 2018-11-30 Grifols Diagnostic Solutions Inc Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante
BR112020016005A2 (pt) 2018-02-07 2020-12-15 Regeneron Pharmaceuticals, Inc. Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN116655791B (zh) * 2023-05-06 2023-11-07 浙江触奇生物科技有限公司 一种抗泌乳素受体的纳米抗体、重组载体、重组菌和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1325930A1 (en) * 2002-01-08 2003-07-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mammal prolactin variants
WO2006110585A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes (prlr)
US7422899B2 (en) 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
ME00588A (en) 2006-08-18 2011-12-20 Prlr-specific antibody and uses thereof
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use

Also Published As

Publication number Publication date
CA2837736C (en) 2018-11-20
WO2012163932A1 (en) 2012-12-06
HUE028775T2 (en) 2017-01-30
MA35237B1 (fr) 2014-07-03
JP5859641B2 (ja) 2016-02-10
TWI548649B (zh) 2016-09-11
AU2012264765A1 (en) 2013-12-19
TN2013000501A1 (en) 2015-03-30
EP2714740B1 (en) 2016-03-30
KR20140036275A (ko) 2014-03-25
HK1195081A1 (zh) 2014-10-31
IL229504A0 (en) 2014-01-30
US9777063B2 (en) 2017-10-03
EA029316B1 (ru) 2018-03-30
IL229504B (en) 2018-10-31
HRP20160506T1 (hr) 2016-06-17
ECSP13013063A (es) 2014-01-31
PE20141158A1 (es) 2014-09-26
EP2530089A1 (en) 2012-12-05
EA201301356A1 (ru) 2014-09-30
ME02659B (me) 2017-06-20
US9353186B2 (en) 2016-05-31
ZA201309683B (en) 2016-08-31
SI2714740T1 (sl) 2016-06-30
CN103764679B (zh) 2016-05-04
RS54727B1 (sr) 2016-10-31
US20160319029A1 (en) 2016-11-03
NZ618316A (en) 2016-01-29
KR101920521B1 (ko) 2018-11-21
CU20130163A7 (es) 2014-04-24
SG195060A1 (en) 2013-12-30
BR112013030995A2 (pt) 2016-11-22
CR20130632A (es) 2014-02-04
EP2714740A1 (en) 2014-04-09
MX2013014174A (es) 2014-11-13
DK2714740T3 (da) 2016-05-30
DOP2013000285A (es) 2014-03-16
CO6852025A2 (es) 2014-01-30
US20140141003A1 (en) 2014-05-22
TW201302798A (zh) 2013-01-16
AR086631A1 (es) 2014-01-08
BR112013030995B1 (pt) 2021-11-09
CN103764679A (zh) 2014-04-30
AU2012264765B2 (en) 2016-07-28
AP2013007266A0 (en) 2013-11-30
JP2014522239A (ja) 2014-09-04
UY34116A (es) 2013-01-03
MX343683B (es) 2016-11-17
CY1117660T1 (el) 2017-05-17
CA2837736A1 (en) 2012-12-06
CL2013003459A1 (es) 2014-08-08
PL2714740T3 (pl) 2016-08-31

Similar Documents

Publication Publication Date Title
ES2572215T3 (es) Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico
CY1121225T1 (el) Συμπυκνωμενες iμιδαζολυλιμιδαζολες ως αντιiκες ενωσεις
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
ECSP13013097A (es) Coagonistas del receptor de glucagón/glp-1
CL2018003597A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos.
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
ES2620264T3 (es) Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer
PE20170665A1 (es) Anticuerpos anti-tau humanizados
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
ES2722799T3 (es) Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
PE20150002A1 (es) Anticuerpos anti-fcrn
PE20161152A1 (es) Anticuerpos y metodos de uso
CL2016002245A1 (es) Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
UY34074A (es) Composición oftálmica de olopatadina altamente concentrada
BR112017008151A2 (pt) construção de gerenciamento de luz
SG195114A1 (en) Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
CO7240431A2 (es) Anticuerpos anti-trka humanizados con sustituciones del aminoacido
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
EA201700136A1 (ru) Полимерная композиция для слоя элемента слоя
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma